Weber G, Cazzuffi M A, Frisone F, de Angelis M, Pasolini D, Tomaselli V, Chiumello G
Istituto Scientifico H San Raffaele, Università degli Studi di Milano, Italia.
Child Nephrol Urol. 1988;9(5):273-6.
In order to study the presence of possible renal damage, 12 patients who had been chronically treated with 1,25-dihydroxycholecalciferol therapy, 1,25(OH)2D3, for hypoparathyroidism, pseudohypoparathyroidism, and hypophosphatemic rickets were examined by renal ultrasound. Two patients had normal values while 10 subjects showed nephrocalcinosis (NC) of mild, medium, or severe degree. The echographic results have been related to some calcium-phosphorus metabolism and therapeutic parameters. In those subjects with medium to severe NC, the age at the beginning of therapy was significantly younger and the dose of 1,25(OH)2D3 was significantly higher, than in the other patients. Laboratory data were not predictive of NC. Renal ultrasound is, therefore, a useful means of screening to detect even early stages of NC; its use in the follow-up is also recommended.
为了研究可能存在的肾损害情况，对12例因甲状旁腺功能减退症、假性甲状旁腺功能减退症和低磷血症性佝偻病而长期接受1,25 -二羟胆钙化醇[1,25(OH)₂D₃]治疗的患者进行了肾脏超声检查。2例患者各项指标正常，而10例患者显示出轻度、中度或重度肾钙质沉着症（NC）。超声检查结果与一些钙磷代谢及治疗参数相关。在那些中度至重度NC患者中，开始治疗时的年龄显著更小，且1,25(OH)₂D₃的剂量显著更高，高于其他患者。实验室数据无法预测NC。因此，肾脏超声是一种有用的筛查手段，甚至可检测到NC的早期阶段；也建议在随访中使用该检查。
